Observational analysis revealed EGFR and TROP2 as significant therapeutic targets in triple-negative breast cancer, suggesting potential for targeted therapies.
Key Points
EGFR and TROP2 expression was elevated in most triple-negative breast cancer samples, highlighting their potential as therapeutic targets.
A positive correlation was noted between EGFR and tissue factor levels, and TROP2 levels were linked with both tissue factor and epithelial cell adhesion molecule levels.
Multiplex immunofluorescence was utilized to assess surface marker expression in tumor specimens from 104 triple-negative breast cancer patients.
Findings emphasize the therapeutic relevance of specific biomarkers, warranting further investigation into targeted treatments for triple-negative breast cancer.